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Abstract
Cell therapy, pioneered for the treatment of malignancies in the
form of bone marrow transplantation, has subsequently been
tested and successfully employed in autoimmune diseases.
Autologous haemopoietic stem cell transplantation (HSCT) has
become a curative option for conditions with very poor prognosis
such as severe forms of scleroderma, multiple sclerosis, and lupus,
in which targeted therapies have little or no effect. The refinement
of the conditioning regimens has virtually eliminated transplant-
related mortality, thus making HSCT a relatively safe choice.
Although HSCT remains a nonspecific approach, the knowledge
gained in this field has led to the identification of new avenues. In
fact, it has become evident that the therapeutic efficacy of HSCT
cannot merely be the consequence of a high-dose immuno-
suppression, but rather the result of a resetting of the abnormal
immune regulation underlying autoimmune conditions. The identifi-
cation of professional and nonprofessional immunosuppressive
cells and their biological properties is generating a huge interest
for their clinical exploitation. Regulatory T cells, found abnormal in
several autoimmune diseases, have been proposed as central to
achieve long-term remissions. Mesenchymal stem cells of bone
marrow origin have more recently been shown not only to be able
to differentiate into multiple tissues, but also to exert a potent
antiproliferative effect that results in the inhibition of immune
responses and prolonged survival of haemopoietic stem cells. All
of these potential resources clearly need to be investigated at the
preclinical level but support a great deal of enthusiasm for cell
therapy of autoimmune diseases.
Rationale for cell therapy for autoimmune
diseases
Chronic inflammatory autoimmune diseases (AD) impart a
massive burden on health services world wide. Efforts to
define new targeted therapies have met with considerable
success [1], yet these approaches are expensive and none of
the new-generation biological agents consistently lead to
prolonged periods of drug-free remission [2,3].
Therapeutic strategies have historically centred on
unconditional systemic immune suppression by virtue of small
molecule inhibitors or immunosuppressive agents. At one
time there was optimism that biological agents that targeted
T cells, such as anti-CD4 or anti-CD3, might be both safer
and have more durable effects for treating patients with
diseases such as rheumatoid arthritis (RA). These agents
target indiscriminately, however, eliminating, or at least
modulating, T cells within the pool of regulatory cells and
pathogen-reactive T cells, as well as the autoreactive lympho-
cyte populations, and their efficacy in placebo-controlled
clinical trials turned out to be disappointing [4,5]. Therapeutic
depletion of a subset of CD20-expressing B cells, which
does not include long-lived autoantibody-producing plasma
cells, has been more promising in a growing number of AD
[6,7], where it has become evident that durability relates to
the efficiency of the depletion phase and the timing of the re-
emergence of pathogenic clonotypes. Nonetheless, even with
prolonged cellular depletion, extended periods of remission
are the exception rather than the rule [8].
Curative therapy therefore remains a major unmet need in the
management of chronic inflammatory disease because it
requires resetting of immune tolerance. This would necessi-
tate depleting the expanded pool of autoreactive T lympho-
cytes and B lymphocytes, retarding the process of immune
senescence in the residual lymphocyte populations, restoring
the integrity of regulatory networks, and, at the same time,
preserving a pool of memory cells capable of responding to
environmental pathogens. Since many programmes of cellular
activation and differentiation are imprinted through epigenetic
mechanisms [9], this process of resetting is not trivial, and is
relatively refractory to external manipulation. Switching
established type 1 T-helper effector responses to a type 2
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response is a good example. Moreover, terminally differen-
tiated lymphocytes and plasma cells have shortened
telomeres with drastically reduced replicative capacity [10],
and therefore therapeutic approaches aimed at targeting cell
division are also likely to fail.
What are the realistic options for achieving a cure in sub-
stantial numbers of patients with established disease? The
emerging paradigm for the treatment of chronic inflammatory
diseases such as RA is early aggressive therapy with tight
control of disease activity aimed at robust suppression of
inflammation [11,12]. More sophisticated manipulation of
effector cell populations including antigen-presenting cells,
T cells, and B cells remains a possibility, but will be limited to
some extent by the re-emergence of pathogenic clones. Now
that technologies for cell purification and protocols for
expanding specific subsets are more advanced, there are
opportunities for achieving immune homeostasis by infusion
of regulatory cell populations, some of which may harbour the
capacity to repair tissues at sites of inflammation.
Reconstitution of the immune system is now a realistic
alternative. In the present article we review and discuss the
current and future prospects for such cell-based therapies.
Hematopoietic stem cell transplantation for
autoimmune diseases
Hematopoietic stem cell transplantation (HSCT) is a treat-
ment aimed at resetting the deregulated immune system of
patients with severe AD [13]. Recent studies have confirmed
that HSCT induces alterations of the immune system that are
beyond the effects of a dose-escalating immunosuppressive
approach. HSCT differs from the so-called targeted therapies
in that HSCT nonspecifically targets a wide array of immuno-
competent cells, and creates space for a new immunological
repertoire, generated from the reinfused and/or residual
hematopoietic stem cells [14].
The acceptance of HSCT in the clinical arena followed
successful studies in experimental animal models of AD [15]
and observations of long-term remissions of AD in patients
treated with HSCT for haematological malignancies [16].
Various protocols have been employed depending on the
underlying disease and on individual experience of transplant
centres, but most involved three consecutive steps. The first
step is the mobilization of peripheral blood progenitor cells
using bolus infusions of cyclophosphamide plus subcu-
taneous injections of granulocyte colony-stimulating factor.
The second step is ‘conditioning’ using high-dose
chemotherapy with or without lympho-depleting antibodies or
total body irradiation. The final step is reinfusion of the
(autologous) graft with or without prior manipulation ex vivo.
The second step is the key therapeutic component, yet the
initial and final steps may affect the safety and effectiveness
of the procedure. For example, the addition of cyclophos-
phamide to granulocyte colony-stimulating factor (first step)
has been shown to diminish the risk of flares of AD [17].
With data from nearly 800 transplant cases registered, the
feasibility of HSCT in human AD has now been firmly
established [18]. The risks of HSCT have decreased
significantly, as illustrated by the gradual drop in transplant-
related mortality in patients with severe systemic sclerosis
(SSc): from 17% in the first cohort of 41 patients from the
European Blood and Marrow Transplant/European League
Against Rheumatism (EBMT/EULAR) registry [19] to 8.7% in a
more recent analysis of 65 patients (which included the 41 first
cohort patients) [20], and 2.5% in the transplant arm of the
ongoing Autologous Stem cell Transplantation International
Scleroderma (ASTIS) trial [21], which is discussed below.
A similar trend has been observed in multiple sclerosis, the
disease that accounts for most cases in the EBMT/EULAR
database. Few unexpected toxicities such as lymphoma and
opportunistic infections have occurred. Nevertheless, major
adverse events have been observed, most notably in SSc,
systemic lupus erythematosus (SLE), and juvenile idiopathic
arthritis. These included respiratory insufficiency during
conditioning (SSc) [22], graft failure (SLE) [17], and macro-
phage activation syndrome (juvenile idiopathic arthritis) [23],
which accounted for the majority of transplant-related
mortality in these diseases. This has led to adjustment of
protocols; for example, less intense T-cell depletion in juvenile
idiopathic arthritis, lung shielding with total body irradiation in
SSc, and exclusion of patients with advanced disease and
irreversible organ dysfunction.
There has been a striking difference between the disease
targeted, the response to intervention, and toxicity, although
differences in regimens and protocols may have acted as a
potential confounder [24]. In general, more intense regimens
were associated with higher transplant-related mortality but
only a slightly lower probability of relapse. Marked improve-
ments of disease activity, functional ability, and quality of life
were seen in the majority of juvenile idiopathic arthritis
patients, resulting in restoration of growth after corticosteroid
therapy was discontinued [25]. Nevertheless, late relapses
have occurred. In SSc, durable skin softening in patients with
established generalized skin thickening has been observed in
two-thirds of patients transplanted, defying conventional
wisdom that fibrotic skin abnormalities are irreversible
[19,20]. In SLE patients, disease activity as measured by the
Systemic Lupus Erythematosus Disease Activity Index
improved markedly [26,27]; and in those patients with pulmo-
nary abnormalities, lung function tests showed significant
improvements in the years following HSCT [28]. In contrast,
most RA patients showed only transient responses, as
measured by scores of disease activity, functional ability,
quality of life, and rate of joint destruction, although the
disease appeared more amenable to antirheumatic
medication post HSCT [29,30].
Two cases of syngeneic HSCT have been reported, one with
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[32], while allogeneic HSCT in another patient also resulted
in a remission of RA [33]. Allogeneic HSCT offers the theo-
retical benefit of replacing the autoaggressive immune system
and utilizing the hypothesized ‘graft versus autoimmunity’
effect [34] in analogy with the established curative graft
versus leukaemia phenomenon, and phase I/II studies are
being planned [35]. Allogeneic HSCT has become less
acutely toxic due to the introduction of nonmyeloablative
conditioning regimens, but the limited availability of matched
donors (siblings), the risk of treatment-related toxicity (graft-
versus-host disease (GvHD)), and mortality (10–30%) put
constraints on the application of this modality.
Building on the experiences from pilot studies, prospective,
multicentre trials have been launched in Europe and the
United States to further investigate the therapeutic value of
autologous HSCT in AD. The first of these, the ASTIS trial
[21], started in 2001 under the auspices of the EBMT/
EULAR to compare the safety and efficacy of HSCT versus
conventional pulse therapy cyclophosphamide in patients
with severe SSc at risk of early mortality. At the time of writing
the present article (December 2006), 81 patients from 20
European centres had been randomized to either HSCT
(n = 38) or to the control arm (n = 43). No unexpected
toxicities or graft failures have been observed to date in either
arm. One patient with heart involvement in the transplant arm
died from progressive heart failure after conditioning,
categorized as a probable transplant-related mortality by the
independent data-monitoring committee.
The North American counterpart of the ASTIS trial, spon-
sored by the National Institutes of Health – the ‘Scleroderma:
Cyclophosphamide or Transplantation’ trial – compares
safety and efficacy of a different transplant regimen versus
intravenous pulse therapy cyclophosphamide. The protocols
of the ASTIS and ‘Scleroderma: Cyclophospha-mide or
Transplantation’ trials are matched with respect to entry
criteria, study parameters, endpoints, and the control arm to
facilitate future analyses [36]. Long-term follow-up of patients
from these trials is crucial in order to monitor potentially late
sequelae or discover delayed diverging trends in (event-free)
survival. Prospective trials in SLE, multiple sclerosis, and
Crohn’s disease are in progress or are being planned. These
trials will determine whether HSCT yields superior clinical
benefit over conventional treatment, and will address open
issues such as the role of post-transplant
immunosuppression, the timing of HSCT, and constituents of
the conditioning regimen (for example, myeloablative versus
nonmyeloablative agents).
The profound immunosuppression resulting from HSCT has
provided an opportunity to study the dynamics of the
reconstituting immune system in relationship with the disease
course. Nevertheless, it has been difficult to relate findings
from immunological monitoring to the disease status, mainly
because of the autologous setting of most transplants, which
makes it impossible to determine the origin of mature
lymphocytes after HSCT (for example, from reinfused versus
residual stem cells, or expanded lymphocytes). Some
patterns have emerged, however: specific autoantibodies did
not always disappear after HSCT despite long-term
remissions. This has been consistently observed for Scl-70
autoantibodies in SSc patients, indicating that these auto-
antibodies were produced by nondividing long-lived plasma
cells. Titres of IgM rheumatoid factor dropped in RA patients
after HSCT, but failed to normalize and returned to pre-
treatment levels before relapse. In SLE patients, antinuclear
antibody and antidouble-stranded DNA antibodies dis-
appeared in many patients after HSCT and returned to
detectable levels during relapse.
HSCT has been shown not only to affect B-cell populations,
but also to profoundly perturb the T-cell compartment, as
illustrated by the normalization of the deregulated T-cell-
receptor repertoires in multiple sclerosis [37].
In the past decade HSCT has evolved from an experimental
concept to a clinically feasible and powerful therapy for
selected patients with severe AD. Multicentre efforts have
shifted from pilot studies and registry analyses to
prospective, controlled trials. These pivotal trials will establish
the position of HSCT in the treatment of AD, will possibly
lead to changes of treatment paradigms, and will help us
better understand pathogenetic mechanisms involved in AD.
Emerging cell therapies
The immune system has developed several strategies to
control unwanted immune responses. During ontogeny,
clonal deletion of autoreactive T cells is the major mechanism
by which the T-cell repertoire is selected [38]. The affinity of
the T-cell receptor for self-peptide–MHC ligands is the
crucial parameter that drives developmental outcome in the
thymus. While progenitor T cells with no affinity or high
affinity for self-peptide–MHC ligands die, those with a low
affinity survive. Potentially autoreactive T cells therefore
persist after thymic selection and further control systems in
the periphery are required to keep them in check. Although
peripheral clonal deletion [39] and anergy [40] contribute to
limit unwanted immune responses, active regulation is the
central mechanism of immunological tolerance in adult life.
Several T-cell subsets have been identified with the ability to
suppress immune responses to a variety of self-antigens and
nonself-antigens. Furthermore, other nonprofessional
suppressor cells have recently been shown to play important
roles in chronic inflammation as well as in tumour
immunosurveillance. Both professional and nonprofessional
suppressor cells have potential for therapeutic exploitation
and are being explored in HSCT to prevent or to treat related
complications, but the suppressor cells have also been
investigated in several animal models of AD. We briefly
discuss the main biological features of each cell type.
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Natural regulatory T (Treg) cells are a subpopulation of
thymus-derived CD4+ T cells that constitutively express the
IL-2 receptor α chain (CD25) [41]. The expression of the
forkhead box P3 gene product is currently the best distinctive
marker for Treg cells [42]. The Treg cells play a crucial role in
the maintenance of peripheral tolerance and they modulate
susceptibility to autoimmune disease [41] and tumour
immunity [43], as well as playing a role in the induction of
transplantation tolerance [44] and in the regulation of
responses to microbes. There is accumulating evidence that
two subsets of CD4+CD25+ Treg cells exist: a cytokine-
independent and antigen-independent naturally occurring
population, and another cell type that is recruited by the
cognate antigen and immunoregulatory cytokines and thus
named adaptive Treg cell [45]. While the former population
derives directly from the thymus, the second derives from
CD4+CD25– T-cell precursors in the periphery.
Several studies have indicated that quantitative or qualitative
abnormalities of Treg cells contribute to the pathogenesis of
AD. Regulatory CD4+CD25+ T cells isolated from patients
with active RA, although displaying an anergic phenotype, are
unable to inhibit proinflammatory cytokine secretion from
activated T cells and monocytes [46]. In experimental models,
the depletion of Treg cells has been shown to exacerbate
chronic inflammatory diseases whereas their adoptive transfer
has been shown to prevent a wide range of experimental AD.
Treg cells have been successfully tested in HSCT for their
ability to control GvHD in animal models, whereby Treg cells
have been shown to prevent GvHD or to increase host
survival when GvHD has been established [47-49]. The
administration of antigen-specific Treg cells generated ex vivo
has similarly been shown to be very effective as sole
immunosuppressive treatment at inducing specific tolerance
to bone marrow allografts [50,51].
The effect of HSCT on Treg cells is largely unknown but there
is evidence that Treg cells are selectively resistant to lympho-
depletion and in fact expand, while the expansion of
potentially pathogenic T cells is prevented as a result of
clonal competition for self-ligands [52]. The numbers of
functionally active CD4+CD25+ Treg cells in juvenile
idiopathic arthritis increase after HSCT, demonstrating that
transplantation restores immunoregulatory mechanisms [53].
This observation is in keeping with preclinical data in a mouse
model of multiple sclerosis, showing that bone marrow
transplantation resulted in increased numbers of
CD4+CD25high Treg cells, increased forkhead box P3
expression, a shift in T-cell epitope recognition, and a strong
reduction of autoantibodies [54].
Natural killer T cells
Another T-cell subset has been identified in mice and humans
with regulatory properties that exhibits natural killer cell
markers. These natural killer T cells use an invariant T-cell
receptor that interacts with synthetic glycolipids such as α-
galactosylceramide in the context of the monomorphic CD1d
antigen-presenting molecule [55]. Invariant natural killer T
cells have the unique capacity to rapidly produce large
amounts of both T-helper 1 and T-helper 2 cytokines, through
which they play important roles in the regulation of
autoimmune, allergic, antimicrobial, and antitumour immune
responses [56]. The in vivo activation of invariant natural killer
T cells with α-galactosylceramide has been tested with some
success in  animal models of various AD such as type 1
diabetes, experimental autoimmune encephalomyelitis, arthritis,
and SLE [57].
Myelo-monocytes
Although cells of the monocyte lineage are generally
regarded as professional antigen-presenting cells, and as
such key players in the induction of immune responses, they
can negatively regulate immune functions when exposed to
particular environments [58]. Furthermore, specific subsets
are intrinsically capable of being suppressive. The ligation of
CD80/CD86 co-stimulatory molecules on certain subsets of
dendritic cells induces the expression of functional indoleamine
2,3-dioxygenase (IDO-competent dendritic cells). IDO is a
haeme-containing enzyme that catabolizes compounds
containing indole rings, such as the essential amino acid
tryptophan. IDO-competent dendritic cells can function as
potent suppressors of T-cell responses both in vivo and in
vitro [59].
Another monocyte subset with immunosuppressive
properties has recently been identified in the tumour setting
and is characterized by the expression of CD11b and Gr-1.
Their accrual has been correlated with the induction of T-
lymphocyte unresponsiveness to antigenic stimulation both in
vitro and in vivo. CD11b+Gr-1+ cells inhibit antigen-activated
T cells through a cognate-independent mechanism that
involves arginase and nitric oxide synthase as the main
effector pathways [60]. These cells are named myeloid
suppressor cells and include a heterogeneous population
ranging from immature myelomonocytic cells to terminally
differentiated monocytes and granulocytes [61]. Tumours
release soluble factors (that is, the cytokines granulocyte–
macrophage colony-stimulating factor, granulocyte colony-
stimulating factor, and IL-3) that contribute to myeloid
suppressor cell recruitment [62], thus accounting in some
cases for the poor outcome of tumour vaccination strategies.
Mesenchymal stem cells
Mesenchymal stem cells (MSC) are cells of stromal origin
that display a variety of features of paramount relevance in the
field of chronic inflammatory diseases. Several reports have
shown that MSC not only differentiate into limb-bud
mesodermal tissues [63], but can also acquire characteristics
of cell lineages outside the limb-bud, such as endothelial cells
[64], neural cells [65], and cells of the endoderm [66].
Whereas in some cases the ability of MSC to provide newly
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gene expression in MSC [66], in other situations it appears
that MSC act through differentiation-independent mechanisms
probably mediated by soluble factors [67]. Despite the efforts
to adopt a consensus definition [68], the identification of
MSC based on the isolation method and the use of specific
markers remains rather loose. A generally accepted profile
includes their ability to differentiate in vitro into multiple
lineages and the expression of CD73, CD105, and CD90 as
well as the absence of haematopoietic markers [69-71]. The
most well studied and accessible source of MSC is bone
marrow, although even in this tissue the cells are present in a
very low frequency. As well as being present in bone marrow,
MSC have also been isolated from peripheral blood, fat, and
synovial tissue [72].
Much interest has recently been generated by the observa-
tion that MSC may also exert a profound immunosuppressive
and anti-inflammatory effect in vitro and  in vivo. Such an
effect is dose dependent and is exerted on T-cell responses
to polyclonal stimuli [73,74] or to their cognate peptide [75].
The inhibition does not appear to be antigen specific [73]
and targets both primary and secondary T-cell responses
[75]. MSC-induced T-cell suppression is not cognate
dependent because it can be observed using class I-negative
MSC [75] and can be exerted by MSC of different MHC
origin from the target T cells [76]. The inhibitory effect of
MSC is directed mainly at the level of cell proliferation as a
result of cyclin D2 downregulation and p27 upregulation
[77,78], and it affects other cells of the immune system
[77,79,80] as well as tumour cells of nonhaematopoieic
origin [81].
The mechanisms underlying the immunosuppressive effect of
MSC remain to be clarified, but they involve mechanisms
mediated by both soluble factors [74,82-84] and cell contact
[75,79,82-85]. Candidate molecules are similar to those
identified in other immunosuppressive cells and include IDO
[84], hepatocyte growth factor, transforming growth factor
beta [74], prostaglandins [86], or nitric oxide [87]. IL-10
secretion by MSC has also been attributed to play a major
role in the immunosuppressive effect by determining a T-
helper 1–T-helper 2 shift [79].
Such immunosuppressive activity does not seem to be
spontaneous but requires MSC to be ‘licensed’ in an
appropriate environment. It has been shown that IFNγ is a
powerful inducer of such activity [88], probably via the
upregulation of IDO [84]. On the contrary, TNFα can reverse
the immunosuppressive activity of MSC in a collagen-induced
arthritis model [89].
MSC have great potential to become a new tool in the list of
cellular therapies for AD. The initial observation that MSC can
exert an immunosuppressive activity in vivo by prolonging
allogeneic skin grafts [73] has been confirmed in animal
models of AD [90], but other workers have reported
opposing results [89]. A common finding is the poor
engraftment of the infused MSC, which could be attributed
either to a natural contraction in their numbers or the use of
allogeneic MSC. There is in fact emerging evidence that the
immunosuppressive activity of MSC does not eventually avoid
their rejection [91,92]. Nevertheless, MSC have been tested
in the clinical setting of HSCT whereby a patient with severe
GVHD of the gut transiently benefited from the infusion of a
third-party MSC from a haplo-identical donor [93]. More
encouraging results are being reported [94].
Mesenchymal stem cells and autoimmune
diseases
AD could be the ideal scenario in which to test the
therapeutic potentials of MSC for their anti-inflammatory
properties. It is still unclear, however, whether MSC derived
from patients with AD display altered functions. Bone-
marrow-derived MSC from RA patients, SLE patients, and
SSc patients were shown to be deficient in their ability to
support haematopoiesis and to exhibit features of early
senescence, possibly as a result of TNFα [95]. Furthermore,
the differentiation potential of MSC into adipogeneic or
osteogenic lineages was reported as impaired in SSc
patients [96]. Recent data similarly suggest that the MSC in
these patients have a defective ability to differentiate into
endothelial precursor cells (R Giacomelli, personal
communication). Despite these faults, MSC derived from the
bone marrow of AD patients have consistently been shown to
retain their immunosuppressive activity [97]. In these
experiments MSC were derived from a variety of AD,
including SSc, RA, and primary Sjoegren’s syndrome. The
possibility of using autologous MSC for therapeutic
application has become important following the
demonstration in nonmyeloablated mice that allogeneic MSC
are immunogenic and can be rejected [91,92].
As already mentioned, some animal models of AD have been
successfully treated by the intravenous infusion of syngeneic
MSC [90,98], as has acute GvHD (Tisato V, et al.,
submitted). In addition, other models of tissue damage such
as ischemia-reperfusion of the kidney [67], bleomycin-induce
lung fibrosis [99], and carbon tetrachloride-induced liver
damage [100] appear to benefit from the early administration
but not late administration of bone marrow MSC. Very limited
data exist regarding the use of MSC in humans, most being
derived from patients treated for acute GvHD [94] and those
receiving MSC post myocardial infarct [101].
Although little is known about the long-term fate of infused
MSC, a common theme is emerging that they may localize in
inflamed and damaged tissue, where they might exert a
protective effect [67], after which they are difficult to detect.
Most knowledge currently comes from limited animal
experiments. Engraftment was estimated to be from 2.7% in
Available online http://arthritis-research.com/content/9/2/206
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tissues [102]. Some MSC may transdifferentiate in situ, but
probably not in sufficient numbers to be of clinical
significance. One recent study of children and adults who
had received either bone marrow or cord-blood transplants
for various disorders looked at the origin of MSC in the bone
marrow up to 192 months following transplant. Donor MSC
were detected from 3 to 17 months in around 30% of the
children, but never in the adults. All children had mixed
chimerism and most had received a fully myeloablative
regimen [103].
Acute toxicity in humans and animals appears minimal. Long-
term toxicity is entirely unknown but may be negligible in view
of the very low level of engraftment. There is evidence,
however, that extensive in vitro passages could expose MSC
to mutations, and in principle the possibility that MSC could
produce tumours when transferred in vivo, as demonstrated
in mice [104]. In the long term MSC might promote tumour
growth either by impairing immune surveillance [83] or by
facilitating tumour survival [81].
Following the preliminary successes of MSC in acute GvHD,
several groups are planning similar studies for the treatment
of AD that have some similarities with GvHD, whereby an
underlying inflammatory, multisystem disorder compromises
the function of vital organs. Unlike acute GvHD patients, AD
patients are not as severely immunosuppressed and the use
of autologous MSC should be considered as the first option.
In vitro data suggest that, at least as far as their immuno-
suppressive activity is concerned, MSC from AD patients are
fully functional. The use of allogeneic, third-party MSC would
probably merely resolve into a short period of ‘salvage and
respite’, as in the case of acute GvHD. These and other
issues such as optimal expansion media (for example, animal
protein free, platelet lysate, autologous serum) and the
source of MSC (bone marrow, cord blood, adipose tissue)
will only be answered by proper randomized studies.
Conclusions
Cell therapies for AD have seen a dramatic development
during the past 10 years, especially with the successful use
of HSCT for otherwise untreatable forms of AD. The recent
identification of cell populations of immune and nonimmune
origin capable of producing profound immunosuppression is
providing new strategies to narrow the specificity of the
immune modulation and, as in the case of MSC, also to
facilitate tissue repair.
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